Brief: NRx Pharmaceuticals Announces Last Patient, Last Visit In Its Phase 2b/3 Trial Of NRX-101 In Suicidal Treatment Resistant Bipolar Depression
04/03/2024 15:13
March 4 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS (NASDAQ: NRXP) ANNOUNCES LAST PATIENT,
LAST
VISIT IN ITS PHASE 2B/3 TRIAL OF NRX-101 IN SUICIDAL TREATMENT
RESISTANT BIPOLAR DEPRESSION
* NRX PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED
AROUND
END OF THIS QUARTER
* NRX PHARMACEUTICALS INC - POSITIVE DATA AND FDA COMMENT
WOULD
TRIGGER NEXT $4 MILLION MILESTONE PAYMENT FROM PARTNERS ALVOGEN
AND LOTUS
Source text for Eikon: ID:nPn2PdFsxa
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview